Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 83.
34. lappuse
... marketing the following drugs : ( 1 ) Aerosol drug products for human use containing 1,1,1 - trichloroethane . ( 2 ) Aerosol drug products containing zirconium . ( 3 ) Amphetamines ( amphetamine , dextroamphetamine , and their salts ...
... marketing the following drugs : ( 1 ) Aerosol drug products for human use containing 1,1,1 - trichloroethane . ( 2 ) Aerosol drug products containing zirconium . ( 3 ) Amphetamines ( amphetamine , dextroamphetamine , and their salts ...
42. lappuse
... marketing . ( c ) Clinical investigations designed to obtain evidence that any drug prod- uct labeled , represented , or promoted as an OTC daytime sedative ( or any similar or related indication ) is safe and effective for the purpose ...
... marketing . ( c ) Clinical investigations designed to obtain evidence that any drug prod- uct labeled , represented , or promoted as an OTC daytime sedative ( or any similar or related indication ) is safe and effective for the purpose ...
43. lappuse
... marketing . In the absence of an approved new drug application , such product is also mis- branded under section 502 of the act . ( c ) Clinical investigations designed to obtain evidence that any drug prod- uct labeled , represented ...
... marketing . In the absence of an approved new drug application , such product is also mis- branded under section 502 of the act . ( c ) Clinical investigations designed to obtain evidence that any drug prod- uct labeled , represented ...
44. lappuse
... marketing . In the ab- sence of an approved new drug applica- tion or abbreviated new drug applica- tion , such product is also misbranded under section 502 of the act . ( c ) Clinical investigations designed to obtain evidence that any ...
... marketing . In the ab- sence of an approved new drug applica- tion or abbreviated new drug applica- tion , such product is also misbranded under section 502 of the act . ( c ) Clinical investigations designed to obtain evidence that any ...
45. lappuse
... marketing . In the absence of an ap- proved new drug application or abbre- viated new drug application , such prod- uct is also misbranded under section 502 of the act . ( c ) Clinical investigations designed to obtain evidence that any ...
... marketing . In the absence of an ap- proved new drug application or abbre- viated new drug application , such prod- uct is also misbranded under section 502 of the act . ( c ) Clinical investigations designed to obtain evidence that any ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning